Transformative Research in Diabetic Nephropathy 2.0
The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect the kidneys. People can join only if they are already having a kidney biopsy or kidney surgery as part of their regular medical care. The main questions this study aims to answer are: * Do people who take SGLT2…
Conditions studied
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
About this study
The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect the kidneys. People can join only if they are already having a kidney biopsy or kidney surgery as part of their regular medical care. The main questions this study aims to answer are: * Do people who take SGLT2 inhibitors show different biological patterns in kidney tissue than similar people who do not take them? * Are these kidney tissue patterns linked with how kidney health changes over time? Researchers will compare participants who take SGLT2 inhibitors with similar participants who do not take these medicines. Participants will: Let researchers use one stored slide of kidney tissue from their regular care (no extra research biopsy) Give a blood sample and a urine sample Let researchers review medical record information over time
Interventions
- Drug: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) — Standard-of-care exposure to sodium-glucose cotransporter 2 inhibitors documented from medication history. Participants are not assigned therapy. Exposure status is used for observational comparisons of kidney tissue molecular and histopathologic features.
- Drug: Renin-angiotensin-aldosterone system blockade — Standard-of-care exposure to renin-angiotensin-aldosterone system blockade documented from medication history for observational comparisons.
- Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA) — Standard-of-care exposure documented from medication history for observational comparisons.
- Drug: Mineralocorticoid Receptor Antagonists(MRAs) — Standard-of-care exposure documented from medication history for observational comparisons.
Primary outcomes
- Change in Kidney Tissue molecular fingerprint (Baseline enrollment to 18 months.)
Eligibility information
Study locations
- Penn Presbyterian Medical Center, Philadelphia, Pennsylvania 19104 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-19.